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Abstract: 35 
Background: English Springer Spaniels (ESS) show an increased risk of chronic hepatitis (CH). In a 36 
previous study of 68 ESS with CH, in which only one dog received corticosteroids, a median survival 37 
time of 189 days was noted. Some ESS with CH appear to improve with prednisolone treatment, 38 
therefore we aimed to investigate the response to prednisolone in this breed. 39 
Participants: ESS with histologically confirmed idiopathic CH were treated with prednisolone 1-40 
2mg/kg/day. Nine female and three male ESS were enrolled (median age at diagnosis of five years). 41 
Patients were monitored clinically and had biochemistry samples taken to assess markers of 42 
hepatocellular damage and function. 43 
Results: The mean starting dose of prednisolone was 1.1mg/kg/day. All symptomatic patients showed 44 
an initial clinical improvement. Two cases were euthanased while receiving prednisolone. The median 45 
time since diagnosis is 1,715 days [range: 672-2,105 days] and the remaining patients are clinically 46 
well, with seven patients still receiving a mean dose of 0.4mg/kg prednisolone every other day. 47 
Statistical analysis demonstrated significant (P<0.05) reductions in serum ALKP, ALT and bilirubin 48 
following 2-4 weeks of prednisolone treatment. 49 
Conclusion: This study demonstrates improved clinical and biochemical parameters when some ESS 50 
with CH are managed with prednisolone and standard supportive treatments. 51 
 52 
Keywords: Hepatology; Canine; Corticosteroids 53 
 54 
 55 
 56 
3 
 
 57 
 58 
Introduction: 59 
English Springer Spaniels (ESS) in the United Kingdom have an increased risk of chronic hepatitis 60 
(CH)¹. CH is defined by the World Small Animal Veterinary Association (WSAVA) Liver 61 
Standardisation Project² as histological evidence of hepatocellular apoptosis, necrosis, regeneration, 62 
predominant mononuclear cell infiltration and fibrosis. The reported post-mortem prevalence of CH in 63 
dogs in first-opinion practice is 12%, suggesting this is a common disease which likely has a range of 64 
aetiologies including nutritional, environmental, genetic and infectious³. There are several well-65 
documented causes of canine CH, such as copper accumulation due to a defect in copper metabolism´ 66 
and possible infectious causes due to Bartonella sppµ, Leptospira spp⁶ and Helicobacter spp ·. 67 
Although previous studies have identified viral causes of CH, including canine adenovirus type I¸ 68 
there is currently no substantial evidence to suggest viral causes are a significant aetiology for canine 69 
CH¹⁻¹². Studies have been performed which support an immune-mediated aetiology to CH in some 70 
breeds¹³⁻¹´. CH has a number of well-reported breed predispositions including the Labrador retriever¹µ, 71 
American cocker spaniel¹¶, English cocker spaniel¹·, ESS¹, Dalmatian¹¸, Doberman pinscher¹¹, Great 72 
Dane²⁰, Cairn terrier and Samoyed¹, however the underlying aetiology is frequently unknown and 73 
therefore treatment often remains non-specific and supportive²¹.  74 
In a previous study of 68 ESS with biopsy confirmed idiopathic CH, only one was treated with 75 
prednisolone, and the median survival time of the whole cohort was 189 days (range: 1 – 1,211 76 
days)²². This suggested that the underlying disease process in the ESS was aggressive and rapidly fatal 77 
in most cases, in contrast to a previous study looking at 79 dogs of various breeds with histologically 78 
confirmed CH which reported mean survival times of 21.1 to 36.4 months when cirrhosis was not 79 
present²³. Research investigating the disease in ESS and other breeds in the UK initially concentrated 80 
on attempts to find a viral cause for the disease because of the histological similarity to human viral 81 
hepatitis and canine acidophil cell hepatitis¹´ ²´. Corticosteroid treatment was not initially advised and 82 
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cases were instead managed supportively. However, the progression of CH in these cases remained 83 
mostly rapid and short survival times were noted²², yet some clinicians reported improved survival 84 
when these cases were given corticosteroids. Despite the widespread use of corticosteroids in the 85 
general treatment of canine CH, only two previous studies have investigated their efficacy²µ⁻²¶. One of 86 
those studies was published prior to the WSAVA Liver Standardisation Project, which generates 87 
concern that some patients were not truly idiopathic, and both studies included a range of canine 88 
breeds. Although both studies identified some clinical and biochemical improvements in some cases 89 
of canine CH, it is likely that the study populations included a diverse range of underlying disease 90 
processes and therefore the results are likely difficult to interpret. There are no currently published 91 
studies investigating the response to prednisolone in canine patients with CH in a single breed. 92 
   Therefore, the authors instituted a prospective cohort study aimed at investigating the clinical and 93 
biochemical response to prednisolone and other supportive treatments in a group of ESS with 94 
histopathologically confirmed idiopathic CH. 95 
 96 
Materials and Methods: 97 
ESS being treated in first-opinion practice, or referred to the Queen’s Veterinary School Hospital 98 
(University of Cambridge) with a histological diagnosis of idiopathic CH were enrolled prospectively 99 
between 2009-2017. No cases had previously been involved in studies investigating CH in ESS. Cases 100 
were identified when veterinary surgeons contacted the authors for advice. A histopathological 101 
diagnosis was based on a predominantly lymphoplasmacytic, interface hepatitis and variable fibrosis, 102 
and according to WSAVA criteria for a diagnosis of CH. All liver biopsies were stained with 103 
rhodanine for qualitative copper assessment using a previously published copper grading system²·. 104 
Samples were scored as grade 1: absence or few copper-containing granules in the cytoplasm of an 105 
occasional hepatocyte; grade 2: obvious copper-containing granules in some centrilobular 106 
hepatocytes; grade 3: numerous granules in most centrilobular hepatocytes (one-third of each lobule); 107 
grade 4: presence of numerous granules in all centrilobular and midzonal hepatocytes (approximately 108 
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two-thirds of the hepatocytes in all lobules); grade 5: abundant granules in more than two-thirds of the 109 
liver cells in all lobules. The histopathology specimens were examined by several board-certified 110 
pathologists and were excluded if significant copper accumulation (grade 3-5) was documented. Cases 111 
with evidence of pyogranulomatous hepatitis were also excluded. No cases had been treated with 112 
corticosteroids within six months of the study. Attending veterinary surgeons gave prednisolone 1-113 
2mg/kg/day and submitted haematology and biochemistry samples and progress reports to the authors. 114 
The prednisolone starting dose range was based on two previous studies that investigated the response 115 
to prednisolone in various canine breeds with chronic hepatitis²µ⁻²¶. Prednisolone is a well-reported 116 
treatment option for canine CH, and the decision to start the patients on this therapy was at the 117 
discretion of the clinician in charge of each case. Informed owner consent was obtained for analysis of 118 
patient data. All patients had their first recheck 2-4 weeks following initiation of prednisolone 119 
therapy, which included biochemical assessment of liver parameters. Further blood samples were 120 
advised to be taken prior to any prednisolone dose reduction. The prednisolone dose was tapered by 121 
25-50% every 4 weeks according to the patient’s clinical and biochemical response, focusing on 122 
alkaline phosphatase (ALKP), alanine aminotransferase (ALT) and bilirubin. While all cases had 123 
these values assessed at diagnosis and at the first recheck, not all cases had these values measured 124 
each time the prednisolone dose was altered. To account for variation in instruments used to assess 125 
biochemical parameters, and corresponding variation in reference ranges, the ALKP, ALT and 126 
bilirubin have been presented as multiples of the upper limit of the reference range for the individual 127 
machine used. Due to individual patient variation in the way prednisolone was tapered and timing of 128 
blood samples, the biochemical values were plotted against the prednisolone dose at the time of 129 
sampling rather than against specific time points. Thus the values were recorded and plotted 130 
graphically against different oral doses of prednisolone, including the values at diagnosis of CH; the 131 
values after prednisolone 1-2mg/kg/day for 2-4 weeks; 0.5-1mg/kg/day; 0.5-1mg/kg/EOD; 0.25-132 
0.5mg/kg/EOD; after cessation of prednisolone treatment (if applicable); and after re-starting 133 
prednisolone treatment if cessation of medication caused a relapse in clinical signs. Additional 134 
therapies used included combinations of s-adenosylmethionine, silybin, ursodeoxycholic acid, 135 
antibiotics and hepatic diet. 136 
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Statistical analysis: 137 
Shapiro-Wilk normality testing was performed on the data and identified a lack of normal distribution, 138 
typical of small data sets. Therefore, the non-parametric two-sided Wilcoxon test was used to 139 
demonstrate significant (P<0.05) changes in serum ALKP, ALT and bilirubin following prednisolone 140 
therapy. 141 
 142 
Results: 143 
Sixteen cases of suspected ESS CH were evaluated during the study period. Two cases were excluded 144 
because hepatic biopsies were not performed, and two cases were excluded because their 145 
histopathology results were not consistent with the previously published WSAVA criteria for CH. 146 
Nine female and three male ESS were enrolled with a median age at diagnosis of five years [range: 11 147 
months-10 years]. All cases had been diagnosed following evaluation of wedge liver biopsies taken 148 
during laparotomy or laparoscopy. Within these cases one dog was being treated with levothyroxine 149 
for hypothyroidism at the time of recruitment, and one case was subsequently diagnosed with protein-150 
losing nephropathy eight months after initially presenting for hepatic disease, and her urine protein 151 
creatinine ratio improved following treatment with standard doses of benazepril (0.5mg/kg SID PO). 152 
Four of the 12 cases showed no clinical signs of CH at diagnosis but were investigated after routine 153 
blood sampling for an unrelated reason detected elevations of liver enzymes. Seven of the 12 cases 154 
had bile culture performed and no bacteria were cultured, however the remaining five patients did not 155 
have this evaluated. Table 1 summarises the histopathological diagnosis for each of the 12 ESS cases 156 
included in the study. None of the 12 ESS displayed significant qualitative copper accumulation 157 
(Table 1) and therefore quantitative copper analysis was not performed in these cases. Furthermore, 158 
there was no histopathological evidence of significant biliary tract inflammation in any of the 159 
evaluated samples from the 12 cases. The mean prednisolone starting dosage was 1.1mg/kg/day 160 
[range: 1.0-2.0mg/kg/day]. Symptomatic patients showed a subjective improvement clinically within 161 
four weeks according to the owners. Table 2 reports the clinical abnormalities reported for each case, 162 
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both at enrolment and at the first recheck appointment, as well as additional treatments provided to 163 
each patient at the time of diagnosis. Two out of the 12 cases were euthanased due to CH-related signs 164 
while receiving prednisolone, with survival times of 122 and 741 days from diagnosis. Clinical signs 165 
that prompted euthanasia for these two patients included hepatic encephalopathy, melaena, jaundice 166 
and lethargy. The remaining ten patients are alive and clinically well at the time of manuscript 167 
submission, with seven patients still receiving a mean dosage of 0.4mg/kg prednisolone every other 168 
day (EOD) [range: 0.25mg/kg/EOD – 1mg/kg/day]. Three patients stopped prednisolone therapy 169 
without a concurrent elevation in liver parameters, while three cases stopped and needed to be 170 
restarted on prednisolone due to recurrence of CH-related signs or an elevation in liver parameters. At 171 
the time of submission, four patients are currently in the process of having their prednisolone dose 172 
reduced with the aim to stop and monitor for recurrence of clinical signs. The median time since 173 
diagnosis for the ten remaining cases is 1,715 days [range: 672-2,105 days]. 174 
Table 3 presents the median values for ALKP, ALT and bilirubin at diagnosis of CH, as well as the 175 
values at the patients’ first recheck 2-4 weeks after starting prednisolone. Two-sided Wilcoxon test 176 
demonstrated a significant reduction in ALKP, ALT and bilirubin at the first recheck following 177 
prednisolone treatment with p-values 0.0010, 0.002 and 0.0156 respectively. Due to variability in the 178 
length of time patients remained on the tapering doses of prednisolone, the authors elected not to 179 
assess for significant changes between the remaining prednisolone doses. 180 
Figures 1 and 2 depict the serum values for ALKP and ALT respectively, from the 12 ESS cases in 181 
this study. In all dogs there were elevations in ALKP and ALT prior to prednisolone treatment, but 182 
following initiation of prednisolone therapy all values significantly reduced for all patients. However, 183 
in the 11 patients that had oral prednisolone reduced to 0.25-0.5mg/kg/EOD or stopped entirely, seven 184 
(64%) documented an increase in either or both ALKP and ALT. In the three cases that had ALKP 185 
measurements following re-starting prednisolone after cessation of treatment, the ALKP values were 186 
subjectively decreased (Figure 1), and the same was found for measured ALT (Figure 2). In five of 187 
the twelve ESS cases, the measured serum ALKP never returned to within the reference range. 188 
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Furthermore, we found that nine of the twelve cases documented serum ALT that did not return to 189 
within the reference range, despite resolution of clinical signs. 190 
Figure 3 presents the values of serum bilirubin in the nine ESS that had these values measured. The 191 
initial values are elevated prior to prednisolone treatment in six patients, and there is a significant 192 
reduction in these values following initiation of prednisolone. Five of the six patients with elevated 193 
serum bilirubin showed a return to normal range, and the one patient whose elevated bilirubin did not 194 
return to normal is still early in the treatment course and has shown a substantial decrease which is 195 
approaching the reference interval. 196 
 197 
Discussion: 198 
This study documents that some ESS with histologically confirmed idiopathic CH show clinical and 199 
clinicopathological improvement to prednisolone 1-2mg/kg/day, in addition to standard supportive 200 
treatments. The median time since diagnosis in our current study was 1,715 days (range: 672 - 2,105 201 
days) and although we cannot make direct comparisons, it does appear that the ESS in our study had 202 
an improved survival compared with the previously documented median survival time of 189 days 203 
(range: 1 - 1,211 days)²². Unfortunately, we do not have a direct control population for comparison, 204 
however given the aggressive nature of ESS CH, and the previously published benefits of 205 
prednisolone for canine CH²⁵ ⁻ ²⁶ , we felt it was inappropriate to deny patients medication that could 206 
benefit them. As a result, we must acknowledge that the supportive treatments provided to the patients 207 
may have contributed to our results. Furthermore, our results suggest that serial measurements of 208 
ALKP, ALT and serum bilirubin are useful for monitoring the patient’s response to prednisolone 209 
therapy, and the increase in some dogs when prednisolone therapy was stopped further supports their 210 
use. This is the first study providing evidence for the use of prednisolone in some ESS with CH and 211 
indeed the first study documenting corticosteroid response in a single rather than multiple breeds²¶. 212 
This positive response was convincing in spite of the absence of a control population without 213 
treatment. These were different dogs from those described in the previous study ²² and offers 214 
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additional support for a female predisposition with nine of the 12 cases being female. Interestingly, 215 
two previous studies¹,²² identified a young to middle-aged onset of disease in ESS (median age at 216 
diagnosis of five years and 3 years 7 months, respectively) which is similar to the median age at 217 
diagnosis in our current study of five years. This is younger than the overall median age of 8 years in 218 
a study of 551 dogs of varying breeds with CH in the UK¹ which had a total of 551 dogs of varying 219 
breeds with CH in the UK. Histologically the liver tissue from ESS CH cases show a predominant 220 
lymphoplasmacytic inflammation with interface hepatitis, variable fibrosis that can extend between 221 
portal triads and hepatocellular apoptosis and necrosis. Whilst it would have been interesting to assess 222 
liver histopathology following treatment with prednisolone, this was not evaluated in the current 223 
study. Table 1 summarises the histopathological diagnosis for each of our 12 ESS cases and the 224 
features identified are remarkably similar to those expected with human autoimmune hepatitis 225 
(AIH)²¸. Hepatic histopathology alone is not considered diagnostic for AIH in humans, but instead 226 
further validation is required with response to immunosuppressive drugs and positive detection of 227 
various serum autoantibodies including non-organ-specific and organ-specific autoantibodies such as 228 
anti-nuclear (ANA), smooth muscle (SMA), liver cytosol type-I (LC-1) and liver-kidney-microsomal 229 
type-I (LKM-1) antibodies²¹. Human leucocyte antigen (HLA) alleles which confer an increased risk 230 
for developing AIH have been found in affected individuals³⁰. These alleles have also been shown to 231 
influence progression of the disease, which is interesting in light of the previously documented 232 
association between dog leukocyte antigen (DLA) and CH in the ESS³¹. Regarding assessment of 233 
hepatic copper, none of the 12 cases were reported to have significant copper accumulation following 234 
qualitative copper grading, however it is possible that variation between the pathologists resulted in a 235 
degree of interobserver variation. However, all pathologists were board-certified and as such are very 236 
likely to have made the authors aware if they had concerns regarding the qualitative copper 237 
assessment of the histopathology specimens. 238 
   An unexpected finding in this study was that four of the 12 cases were perceived to be 239 
asymptomatic at the time of diagnosis, in contrast to a previous case series suggesting that the disease 240 
is usually aggressive and rapidly fatal²². These patients may have been identified early in the course of 241 
10 
 
their disease and it is possible they will have become clinically unwell in the future if the disease had 242 
not been investigated. Human AIH has an asymptomatic presentation in 25-34% cases³², with 26-70% 243 
of these patients going on to develop clinical signs within 32 months of diagnosis. The number of 244 
asymptomatic cases in our current study is not too dissimilar from that reported in human literature 245 
which could suggest some similarities between human AIH and ESS CH. It is impossible to know in 246 
either humans or dogs how long a patient may be asymptomatic prior to clinical presentation because 247 
patients without symptoms are not routinely blood tested. An equally unexpected finding was the 248 
significant reduction in ALKP in patients despite prednisolone therapy. It is known that 249 
corticosteroids induce ALKP activity in dogs, and therefore it is common for patients treated with 250 
prednisolone to experience increased serum concentrations of the enzyme³³. The significant reduction 251 
in serum ALKP seen in our cohort following initiation of prednisolone treatment suggests that, in 252 
these cases, the initial enzyme elevation prior to corticosteroid administration was primarily disease 253 
induced. Therefore, controlling the disease with prednisolone appeared to result in a corresponding, 254 
significant reduction in hepatocellular damage and cholestasis. The continued mild elevations in ALP 255 
on treatment are consistent with steroid induction of enzymes supported by the fact that bilirubin 256 
became normal in six cases.  257 
We recognise there are limitations to this investigation. Due to the clinical nature of this cohort study, 258 
with individual patients being managed by different veterinarians, there was some variability in the 259 
way prednisolone was tapered and timing of blood samples. Therefore, the authors did not plot the 260 
measured serum values of ALT, ALKP and bilirubin against time from initiation of treatment, but 261 
instead the values were plotted against different doses of prednisolone. Furthermore, all cases 262 
received additional supportive medications for CH which varied between patients and could have 263 
influenced results. However, this variability is inherently difficult to overcome when dealing with 264 
patients in clinical practice and also made it challenging to accurately standardise a clinical scoring 265 
system. It is also important to note that cases were enrolled at different times which resulted in 266 
patients being at different stages of their disease with some having fully recovered while others 267 
having more recently been diagnosed and started on medication at the time of manuscript submission.  268 
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 269 
Conclusion: 270 
This study documents that some ESS with histologically confirmed idiopathic CH show clinical and 271 
clinicopathological improvement to prednisolone 1-2mg/kg/day, in addition to standard supportive 272 
dietary and medical management. Further studies are indicated to investigate potential serum markers 273 
of autoimmunity and the use of other immunosuppressive treatments in affected dogs. 274 
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Tables: 373 
 374 
Table 1: Histopathological diagnosis for each of the twelve English Springer Spaniels included in the 375 
study. 376 
 377 
 378 
 379 
 380 
 381 
 382 
 383 
 384 
 385 
 386 
 387 
 388 
Patient: Histopathological diagnosis: 
1 Hepatitis, interface, lymphocytic, plasmacytic and neutrophilic, chronic, mild, with 
moderate to marked hepatocyte apoptosis. Grade 1 copper. 
2 Hepatitis, periportal, lymphocytic and neutrophilic, chronic, marked, with moderate 
porto-portal bridging fibrosis. Grade 2 copper. 
3 Hepatitis, lymphocytic, plasmacytic and neutrophilic, chronic, moderate, with 
moderate hepatocyte apoptosis and necrosis. Grade 2 copper. 
4 Hepatitis, interface, lymphocytic, plasmacytic and neutrophilic, chronic, severe, with 
mild porto-portal bridging fibrosis. Grade 2 copper. 
5 Hepatitis, periportal, lymphocytic and neutrophilic, chronic, marked with moderate 
hepatocyte apoptosis and necrosis. Grade 2 copper. 
6 Hepatitis, periportal, lymphocytic, plasmacytic and neutrophilic, chronic, marked, 
with mild porto-portal bridging fibrosis. Grade 1 copper. 
7 Hepatitis, interface, lymphocytic, plasmacytic and neutrophilic, chronic, severe, with 
mild biliary hyperplasia and hepatocyte necrosis. Grade 2 copper. 
8 Hepatitis, lymphocytic, plasmacytic, chronic, moderate, with moderate porto-portal 
bridging fibrosis. Grade 1 copper. 
9 Hepatitis, lymphocytic, plasmacytic, chronic, moderate, with moderate portal 
fibrosis and portal biliary hyperplasia. Grade 1 copper. 
10 Hepatitis, lymphocytic, plasmacytic, subacute, moderate. Grade 2 copper. 
11 Hepatitis, lymphocytic, plasmacytic and neutrophilic, subacute, moderate, with 
occasional pigmented histiocytes and mild hepatocyte apoptosis. Grade 2 copper. 
12 Hepatitis, lobular and interface, lymphocytic and neutrophilic, chronic, severe with 
mild portal fibrosis. Grade 1 copper. 
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Table 2: Clinical signs documented for each of the twelve English Springer Spaniels reported in the 389 
study, both at enrolment and at the first recheck appointment (2-4 weeks after initiation of 390 
prednisolone therapy) with additional treatments: 391 
Patient: Clinical signs at 
diagnosis: 
Clinical signs at first 
recheck: 
Additional treatments: 
1 Reduce appetite, 
vomiting, jaundice. 
Resolution of jaundice and no 
abnormal clinical signs 
currently reported by owner. 
UDCA, SAMe, amoxicillin-
clavulanate 
2 PUPD. Resolution of PUPD according 
to owner. 
UDCA, SAMe 
3 Anorexia, PUPD, 
vomiting, weight-
loss, jaundice, 
lethargy. 
Jaundice still identified during 
clinical examination and 
appetite improved but 
reduced compared to normal. 
Resolution of vomiting, PUPD 
and lethargy according to 
owner, however weight-loss 
continued. The patient 
subsequently developed 
neurological abnormalities 
with worsening jaundice, and 
was euthanised 122 days after 
initiating prednisolone 
therapy. 
UDCA, SAMe, 
metronidazole 
4 Lethargy, reduced 
appetite, vomiting, 
jaundice. 
Jaundice not identified during 
clinical examination and no 
abnormal signs currently 
reported by the owner. 
UDCA, SAMe 
5 No abnormal clinical 
signs reported by 
owner.  
Still reported to be clinically 
normal by owner. 
UDCA, SAMe, hepatic diet 
6 No abnormal clinical 
signs reported by 
owner. 
Still reported to be clinically 
normal by owner. 
SAMe, hepatic diet 
7 No abnormal clinical 
signs reported by 
owner. 
Still reported to be clinically 
normal by owner. 
SAMe 
8 Jaundice, ascites, 
weight-loss. 
Resolution of jaundice and 
ascites during clinical 
examination. No abnormal 
signs currently reported by 
the owner. The patient 
subsequently developed 
neurological abnormalities 
and melaena, and was 
euthanised 741 days after 
initiating prednisolone 
therapy. 
UDCA, SAMe, 
spironolactone 
9 Reduced appetite 
and PUPD. 
PUPD still present but 
improved, according to 
UDCA, SAMe 
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*PUPD: polyuria/polydipsia; UDCA: ursodeoxycholic acid; SAMe: S-adenosylmethionine 392 
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Table 3: Median values for serum alkaline phosphatase (ALKP), alanine aminotransferase (ALT) and 416 
bilirubin in English Springer Spaniels at diagnosis of CH, and at first recheck (2-4 weeks after 417 
initiation of prednisolone 1-2mg/kg/day). 418 
owner. Appetite now normal. 
10 No abnormal clinical 
signs reported by 
owner. 
Still reported to be clinically 
normal by owner. 
 
11 Vomiting, lethargy, 
jaundice, ascites, 
PUPD. 
Mild PUPD and polyphagia 
reported by owner, otherwise 
no abnormal clinical signs. 
Hepatic diet 
12 Lethargy, diarrhoea, 
vomiting. 
Resolution of vomiting and 
diarrhoea but owner still 
reported mild lethargy. 
SAMe, hepatic diet, 
cefalexin 
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*The values are reported as a multiple of the upper limit of the reference range. 425 
 426 
 427 
 428 
 429 
 430 
 431 
 432 
 433 
 434 
 435 
 436 
 437 
 438 
 439 
 440 
 441 
 442 
 443 
 444 
 445 
 446 
 447 
 448 
Figure legends: 449 
 450 
 Median value* at 
diagnosis (range) 
Median value* at 
first recheck (range) 
P-Value 
ALKP  8.5 (3.7 - 16.2) 2.7 (1.1 - 8.3) 0.0010 
ALT  10.8 (2.5 – 46.3) 3.9 (0.8 – 14.7) 0.0020 
Bilirubin  1.4 (0.3 – 27.9) 0.45 (0.1 – 4.1) 0.0156 
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Figure 1: Serum [ALKP] as a multiple of the upper limit of the reference range in 12 ESS with CH, at 451 
diagnosis (before prednisolone treatment), first recheck (2-4 weeks after starting 1-2mg/kg/day 452 
prednisolone) and at tapering doses of prednisolone. A significant difference was identified between 453 
the values at diagnosis and first recheck, however due to variability of dosing the authors did not 454 
assess statistical differences between the remaining prednisolone doses. Each coloured shape 455 
represents an individual patient. *EOD: every other day. 456 
 457 
Figure 2: Serum [ALT] as a multiple of the upper limit of the reference range in 12 ESS with CH, at 458 
diagnosis (before prednisolone treatment), first recheck (2-4 weeks after starting 1-2mg/kg/day 459 
prednisolone) and at tapering doses of prednisolone. A significant difference was identified between 460 
the values at diagnosis and first recheck, however due to variability of dosing the authors did not 461 
assess statistical differences between the remaining prednisolone doses. Each coloured shape 462 
represents an individual patient. *EOD: every other day. 463 
 464 
Figure 3: Figure 3: Serum [bilirubin] as a multiple of the upper limit of the reference range in 9 ESS 465 
with CH, at diagnosis (before prednisolone treatment), first recheck (2-4 weeks after starting 1-466 
2mg/kg/day prednisolone) and at tapering doses of prednisolone. A significant difference was 467 
identified between the values at diagnosis and first recheck, however due to variability of dosing the 468 
authors did not assess statistical differences between the remaining prednisolone doses. Each coloured 469 
shape represents an individual patient. *EOD: every other day. 470 
